Survival impact of sequential chemotherapy following pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma-Reference-Cited by-同舟云学术

Survival impact of sequential chemotherapy following pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma

Published:2024-03-30 Issue:6 Volume:29 Page:764-770
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Iwaki Sho,Kadowaki Shigenori^ORCID,Honda Kazunori,Narita Yukiya,Masuishi Toshiki,Taniguchi Hiroya,Ando Masashi,Muro Kei,Sawabe Michi,Suzuki Hidenori,Nishikawa Daisuke,Beppu Shintaro,Terada Hoshino,Kishikawa Toshihiro,Kawakita Daisuke,Hanai Nobuhiro

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10147-024-02508-0.pdf

Reference20 articles.

1. Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127

2. Ferris RL, Blumenschein G Jr, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856–1867

3. Burtness B, Harrington KJ, Greil R et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394:1915–1928

4. Saleh K, Daste A, Martin N et al (2019) Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer 121:123–129

5. Wakasaki T, Yasumatsu R, Uchi R et al (2020) Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma. Auris Nasus Larynx 47:116–122